Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Nov 05, 2024 10:26pm
111 Views
Post# 36298030

RE:RE:China Daily Article

RE:RE:China Daily Article

Maybe... just maybe...

...Kellum is "getting extra picky" on the last 20 or so...perhaps in anticipation that the  CG due diligence on Vantive will stretch into Q1 ( as Baxter has already warned may be the case) 

If CG wants both Vantive and Spectral as a key part of their go forward strategy - they don't want the word out on the street about Tigris before the Vantive buyout finalization. ( eg could invite competitors for pMX, a desire to preserve as much of the "sizzle" as possible for a later date, etc.). Though interesting there is some perhaps loose-lipmanship going on by the new Vantive CEO. 

A possible and logical sequence as I see it:

-CG closes on Vantive (Q1)
-TOP Line on Tigris is released ( shortly thereafter )
-CG makes an offer for Spectral shares ( shortly thereafter) 
-Offer accepted by > 50% SH vote ( in the bag)
-FDA makes its final official decision on the fast tracked PMX ( mid 2025?)
-Vantive as the new owner of NA rights to PMX  ( wider?) then sells the sizzle to boost the value of Vantive ( IPO in the future?)  Imagine  (1) maybe worldwide distro. rights to PMX, (2) worldwide rights to the companion diagnostic-  EAA, (3) a cleared PrisMax pump for HP ( and with the only logical competitor tamped down), and (4) owning the one-two Sepsis punch of OXiris and PMX. If achieved, the world is their oyster! 

Analogy. When Buying a house... Less subsequent offers come in for a house that has a conditional offer on it. And as a buyer you don't want the word getting out that the house may be sitting on a gold mine. 

jus spectralating/theorizing here. I could be totally wrong.   Dyodd. 


MM

<< Previous
Bullboard Posts
Next >>